Patent 10874304

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

Mohammed N. Islam, Sc.D. The inventor is noted as a tenured Professor of Optics and Photonics and Professor of Biomedical Engineering at the University of Michigan, and is also the founder and Chief Technology Officer for several companies, including Omni MedSci, Inc. and Cheetah Omni.

Original assignee

Omni Medsci Inc. is the entity named as the original assignee on the issued patent US10874304 and remains the current assignee. It is unclear if Omni Medsci Inc. ships a product embodying the claims of this patent. While the company is described as part of "the Omni family of companies, which create, develop, and commercialize Dr. Islam's optical technology in various fields", and a related entity, Omni Sciences Inc., works on developing and marketing lasers, Omni Medsci Inc. itself has been identified as a Non-Practicing Entity (NPE) by Unified Patents. The primary line of business for Omni Medsci Inc. appears to be the development and commercialization of optical technology, significantly through patent licensing and assertion in the healthcare and medical device sectors. Omni Medsci Inc. is currently an operating entity, actively asserting its patents, including US10874304, in multiple litigation campaigns.

Assignment timeline

No post-issuance assignments for US10874304 have been recorded in the USPTO Patent Assignment Search database. The patent was assigned by the inventor, Mohammed N. Islam, to Omni Medsci Inc. on the application filing date (2019-10-31), as indicated in the Google Patents legal events.

Timeline diagram

timeline
    title Ownership of US 10874304
    2019 : Application filed by Omni Medsci Inc
    2020 : Patent issued to Omni Medsci Inc
    2024 : Litigation filed in E.D. Texas
    2025 : Litigation filed in D. Delaware
         : PTAB IPR2025-01584 filed
         : PTAB IPR2025-01251 filed

NPE / troll-pattern signals

  1. Shell-entity transfer — unclear
    While Omni Medsci Inc. is identified as an NPE by Unified Patents and its business model appears centered on patent assertion, there is no recorded transfer of US10874304 from a clear operating company to a shell entity in the USPTO assignment records. The patent was assigned by the inventor directly to Omni Medsci Inc. at the time of application filing. Although other patents by the same inventor have seen transfers between various "Omni family" LLCs, this specific patent's direct chain does not show such a transfer.

  2. Known asserter in the chain — present
    Omni Medsci Inc. is currently asserting US10874304 in multiple infringement lawsuits against companies such as Fossil, OnePlus, Oura Health, Samsung, and WHOOP. Unified Patents explicitly designates Omni Medsci Inc. as an NPE.

  3. Repeat correspondent across the chain — unclear
    As there are no recorded post-issuance assignments for US10874304 in the USPTO database, there is no assignment chain to evaluate for recurring correspondent attorneys or firms.

  4. Cascading transfers — not present
    No cascading transfers are present, as there are no recorded post-issuance assignments for US10874304.

  5. Pre-litigation transfer — not present
    No pre-litigation transfer is present. The patent was assigned to Omni Medsci Inc. at the time of application filing in 2019, while the earliest identified litigation for this patent began in 2024.

  6. Bankruptcy fire-sale — not present
    There is no information in the provided sources indicating that Omni Medsci Inc. has filed for bankruptcy or that the patent was acquired through a bankruptcy sale.

  7. Privateering — unclear
    While Omni Medsci Inc. is an NPE asserting patents from its founder, Mohammed Islam, there is no explicit evidence from the provided sources to confirm that this assertion is conducted on behalf of an operating company against its competitors.

  8. Defensive aggregator (anti-NPE) — not present
    The patent is currently owned and actively asserted by Omni Medsci Inc., not by a defensive aggregator. Unified Patents, a defensive aggregator, has in fact initiated prior art contests targeting Omni Medsci's patents, identifying them as NPEs.

Verdict

NPE — high confidence
The current assignee, Omni Medsci Inc., is a known patent asserter explicitly identified as an NPE by Unified Patents. This patent, US10874304, is central to ongoing infringement litigation campaigns initiated by Omni Medsci Inc. in 2024 (e.g., Eastern District of Texas case 2:24-cv-01070) and 2025 (e.g., Delaware District Court case 1:25-cv-00140), among other legal challenges. This extensive and sustained litigation activity, combined with the NPE designation, strongly supports the conclusion that Omni Medsci Inc. operates primarily as a patent licensing and assertion entity rather than a product-shipping company.

USPTO Assignment Center search page: https://assignmentcenter.uspto.gov/

Generated 5/24/2026, 12:48:14 PM